Exploiting the Metabolism of the Gut Microbiome as a Vehicle for Targeted Drug Delivery to the Colon

Hamid A. Bakshi; Gerry A. Quinn; Alaa A. A. Aljabali; Faruck L. Hakkim; Rabia Farzand; Mohamed M. Nasef; Naji Abuglela; Prawej Ansari; Vijay Mishra; Ángel Serrano-Aroca; Murtaza M. Tambuwala

doi:10.3390/ph14121211

Exploiting the Metabolism of the Gut Microbiome as a Vehicle for Targeted Drug Delivery to the Colon

Hamid A. Bakshi
, Gerry A. Quinn
, Alaa A. A. Aljabali
, Faruck L. Hakkim
, Rabia Farzand
, Mohamed M. Nasef
, Naji Abuglela
, Prawej Ansari
, Vijay Mishra
, Ángel Serrano-Aroca
, Murtaza M. Tambuwala

Research output: Contribution to journal › Review article › peer-review

22 Citations (Scopus)

128 Downloads (Pure)

Abstract

The prevalence of colon-associated diseases has increased significantly over the past several decades, as evidenced by accumulated literature on conditions such as Crohn’s disease, irritable bowel syndrome, colorectal cancer, and ulcerative colitis. Developing therapeutics for these diseases is challenging due to physiological barriers of the colon, systemic side effects, and the intestinal environment. Therefore, in a search for novel methods to overcome some of these problems, researchers discovered that microbial metabolism by gut microbiotia offers a potential method for targeted drug delivery This overview highlights several drug delivery systems used to modulate the microbiota and improve colon-targeted drug delivery. This technology will be important in developing a new generation of therapies which harness the metabolism of the human gut microflora.

Original language	English
Article number	1211
Pages (from-to)	1-14
Number of pages	14
Journal	Pharmaceuticals
Volume	14
Issue number	12
Early online date	23 Nov 2021
DOIs	https://doi.org/10.3390/ph14121211
Publication status	Published (in print/issue) - 31 Dec 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

colon
gut microflora
oral drug delivery
gastrointestinal technology
genetically modified bacteria
probiotics
gut metabolism
colon targeted delivery

Access to Document

10.3390/ph14121211Licence: CC BY

pharmaceuticals-14-01211-v2.pdfFinal published version, 0.98 MBLicence: CC BY

Cite this

@article{becf2fe100f54df3a846011c29fcf38b,

title = "Exploiting the Metabolism of the Gut Microbiome as a Vehicle for Targeted Drug Delivery to the Colon",

abstract = "The prevalence of colon-associated diseases has increased significantly over the past several decades, as evidenced by accumulated literature on conditions such as Crohn{\textquoteright}s disease, irritable bowel syndrome, colorectal cancer, and ulcerative colitis. Developing therapeutics for these diseases is challenging due to physiological barriers of the colon, systemic side effects, and the intestinal environment. Therefore, in a search for novel methods to overcome some of these problems, researchers discovered that microbial metabolism by gut microbiotia offers a potential method for targeted drug delivery This overview highlights several drug delivery systems used to modulate the microbiota and improve colon-targeted drug delivery. This technology will be important in developing a new generation of therapies which harness the metabolism of the human gut microflora.",

keywords = "colon, gut microflora, oral drug delivery, gastrointestinal technology, genetically modified bacteria, probiotics, gut metabolism, colon targeted delivery",

author = "Bakshi, \{Hamid A.\} and Quinn, \{Gerry A.\} and Aljabali, \{Alaa A. A.\} and Hakkim, \{Faruck L.\} and Rabia Farzand and Nasef, \{Mohamed M.\} and Naji Abuglela and Prawej Ansari and Vijay Mishra and {\'A}ngel Serrano-Aroca and Tambuwala, \{Murtaza M.\}",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

month = dec,

day = "31",

doi = "10.3390/ph14121211",

language = "English",

volume = "14",

pages = "1--14",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "Multidisciplinary Digital Publishing Institute",

number = "12",

}

TY - JOUR

T1 - Exploiting the Metabolism of the Gut Microbiome as a Vehicle for Targeted Drug Delivery to the Colon

AU - Bakshi, Hamid A.

AU - Quinn, Gerry A.

AU - Aljabali, Alaa A. A.

AU - Hakkim, Faruck L.

AU - Farzand, Rabia

AU - Nasef, Mohamed M.

AU - Abuglela, Naji

AU - Ansari, Prawej

AU - Mishra, Vijay

AU - Serrano-Aroca, Ángel

AU - Tambuwala, Murtaza M.

PY - 2021/12/31

Y1 - 2021/12/31

N2 - The prevalence of colon-associated diseases has increased significantly over the past several decades, as evidenced by accumulated literature on conditions such as Crohn’s disease, irritable bowel syndrome, colorectal cancer, and ulcerative colitis. Developing therapeutics for these diseases is challenging due to physiological barriers of the colon, systemic side effects, and the intestinal environment. Therefore, in a search for novel methods to overcome some of these problems, researchers discovered that microbial metabolism by gut microbiotia offers a potential method for targeted drug delivery This overview highlights several drug delivery systems used to modulate the microbiota and improve colon-targeted drug delivery. This technology will be important in developing a new generation of therapies which harness the metabolism of the human gut microflora.

AB - The prevalence of colon-associated diseases has increased significantly over the past several decades, as evidenced by accumulated literature on conditions such as Crohn’s disease, irritable bowel syndrome, colorectal cancer, and ulcerative colitis. Developing therapeutics for these diseases is challenging due to physiological barriers of the colon, systemic side effects, and the intestinal environment. Therefore, in a search for novel methods to overcome some of these problems, researchers discovered that microbial metabolism by gut microbiotia offers a potential method for targeted drug delivery This overview highlights several drug delivery systems used to modulate the microbiota and improve colon-targeted drug delivery. This technology will be important in developing a new generation of therapies which harness the metabolism of the human gut microflora.

KW - colon

KW - gut microflora

KW - oral drug delivery

KW - gastrointestinal technology

KW - genetically modified bacteria

KW - probiotics

KW - gut metabolism

KW - colon targeted delivery

UR - https://www.scopus.com/pages/publications/85119953265

U2 - 10.3390/ph14121211

DO - 10.3390/ph14121211

M3 - Review article

C2 - 34959610

SN - 1424-8247

VL - 14

SP - 1

EP - 14

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 12

M1 - 1211

ER -

Exploiting the Metabolism of the Gut Microbiome as a Vehicle for Targeted Drug Delivery to the Colon

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Insulinotropic and antidiabetic properties of traditional Asian medicinal plants for the treatment of type 2 diabetes: insulinotropic and antidiabetic properties of phytochemicals

Molecular analysis of the effects of crocin on acute myeloid leukaemia, pancreatic and colon cancer

Cite this

Exploiting the Metabolism of the Gut Microbiome as a Vehicle for Targeted Drug Delivery to the Colon

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Student theses

Insulinotropic and antidiabetic properties of traditional Asian medicinal plants for the treatment of type 2 diabetes: insulinotropic and antidiabetic properties of phytochemicals

Molecular analysis of the effects of crocin on acute myeloid leukaemia, pancreatic and colon cancer

Cite this